Sestrin2 Is Increased in Calcific Aortic Disease and Inhibits Osteoblastic Differentiation in Valvular Interstitial Cells via the Nuclear Factor E2–related Factor 2 Pathway

Haixiong Wang, MD,* Jicheng Xi, MD,* Zhibiao Zhang, MD,* Jun Li, MD,* Liping Guo, MD,* Na Li, MD,* Yuehui Sun, MD,* Xiaofang Li, MD,† and Xuebin Han, MD*

Abstract: Sestrin2 (Sesn2) is involved in the progression of cardiovascular diseases, such as hypertension and myocardial infarction. This study aimed to examine Sesn2 expression in human calcific aortic valve disease (CAVD) and explore its possible mechanisms by which Sesn2 participates in this process. CAVD and normal aortic valves were collected. Sesn2 expression and sources were examined, and the results showed that Sesn2 expression was increased in aortic valves from patients with CAVD and was mainly secreted by macrophages. Additionally, U937 macrophages were pretreated with si-Sesn2 or cDNA-Sesn2 and further treated with oxidized low-density lipoprotein (ox-LDL); M1 macrophages and their markers were measured, and we found that pretreatment with si-Sesn2 increased ox-LDL–induced M1 macrophage polarization and marker mRNA levels, whereas pretreatment with cDNA-Sesn2 had the opposite effects. In ox-LDL–treated U937 macrophages, oxidative stress levels were increased in the si-Sesn2 pretreatment group and further increased by si-Nrf2 treatment, whereas oxidative stress levels were decreased in the cDNA-Sesn2 pretreatment group and significantly reversed by ML385, a specific Nrf2 inhibitor. The effects of Sesn2 on ox-LDL–induced oxidative stress and the osteogenic differentiation of ox-LDL–induced valvular interstitial cells (VICs) was examined by down-regulating Nrf2 pathway. When U937 macrophages were co-cultured with VICs, downregulation of Sesn2 increased ox-LDL–induced osteogenic differentiation in VICs, whereas overexpression of Sesn2 exerted the opposite effects. Our study suggests that Sesn2 is increased in CAVD aortic valves and may participate in the development of CAVD by regulating oxidative stress via the Nrf2 pathway.

Key Words: calcific aortic disease, Sestrin2, M1 macrophage polarization, oxidative stress, valvular interstitial cell osteoblastic differentiation

(J Cardiovasc Pharmacol™ 2022;80:609–615)

INTRODUCTION

Calcific aortic valve disease (CAVD) is a common public health problem in elderly individuals in both developed and developing countries, and valve calcification is the main clinical feature.† Studies have shown that CAVD can result in more than 23,000 deaths per year in the United States, and although the number is lower in China, its incidence is still rising.‡ To date, no drugs have been found to delay the progression or improve the prognosis of CAVD. Aortic valve replacement may be the only effective treatment, but it is expensive and difficult for older patients to tolerate.¶

Sestrin2 (Sesn2) is an antioxidant protein that has been reported to be widely expressed in many organs and tissues in mammals. Evidence has confirmed that although both immune cells and nonimmune cells can secrete Sesn2, immune cells are still the main sources of Sesn2, especially macrophages.§ The expression of Sesn2 can be regulated by a variety of pathological factors, especially the oxidative stress.© Previous studies reported that Sesn2 expression is positively correlated with oxidative stress levels, suggesting that Sesn2 levels increase when oxidative stress levels increase.© Sesn2 can regulate many systemic diseases by regulating oxidative stress levels.‖ †† Data from animal studies and clinical experiments have shown that Sesn2 can participate in the progression of a variety of cardiovascular diseases. Yang et al.‡‡ reported that deletion of the dopamine D2 receptor could increase blood pressure in mice, and silencing of Sesn2 could further elevate blood pressure. In a mouse heart ischemia–reperfusion model, knockout or downregulation of Sesn2 expression significantly increased the myocardial infarction areas.‡§ In a mouse model of cardiac fibrosis induced by ultraviolet radiation, Sesn2

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Correspondence: Xuebin Han, Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China (e-mail: hanxuebin669799@163.com) or Xiaofang Li, Department of Digestive Oncology, Shanxi Bethune Hospital, Taiyuan, Shanxi, China (e-mail: lx838428781@163.com).

Supporting information can be found in the online version of this article.

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.

The online version of this article, along with supplementary data and other material, can be found at www.jcvp.org.

Haixiong Wang, MD,* Jicheng Xi, MD,* Zhibiao Zhang, MD,* Jun Li, MD,* Liping Guo, MD,* Na Li, MD,* Yuehui Sun, MD,* Xiaofang Li, MD,† and Xuebin Han, MD*

Received for publication January 8, 2022; accepted May 6, 2022.

From the *Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China; and †Department of Digestive Oncology, Shanxi Bethune Hospital, Taiyuan, Shanxi, China.

Supported by the Shanxi Provincial Health Commission “Four Batch Science and Technology Innovation Project of Medical Development (No. 2021XM45 to H. Wang), Natural Science Foundation of Shanxi Province (No. 2021030213346 to H. Wang), and Academic promotion plan of Shanxi Cardiovascular Hospital (No. XYS20180102 to H. Wang).

†H. Wang and J. Xi contributed equally to this work.

**Data from animal studies and clinical experiments have shown that Sesn2 can participate in the progression of a variety of cardiovascular diseases. Yang et al.‡‡ reported that deletion of the dopamine D2 receptor could increase blood pressure in mice, and silencing of Sesn2 could further elevate blood pressure. In a mouse heart ischemia–reperfusion model, knockout or downregulation of Sesn2 expression significantly increased the myocardial infarction areas.‡§ In a mouse model of cardiac fibrosis induced by ultraviolet radiation, Sesn2 co-cultured with VICs, downregulation of Sesn2 increased ox-LDL–induced osteogenic differentiation in VICs, whereas overexpression of Sesn2 exerted the opposite effects. Our study suggests that Sesn2 is increased in CAVD aortic valves and may participate in the development of CAVD by regulating oxidative stress via the Nrf2 pathway.

Key Words: calcific aortic disease, Sestrin2, M1 macrophage polarization, oxidative stress, valvular interstitial cell osteoblastic differentiation

(J Cardiovasc Pharmacol™ 2022;80:609–615)
deficiency further increased cardiac fibrosis marker expression.\textsuperscript{14} Liu et al reported that Sesn2 was increased in both the plasma and the aortas of aortic dissection patients and may participate in aortic dissection by reducing vascular smooth muscle cell apoptosis via the Nrf2 pathway.\textsuperscript{6} In our previous study, plasma Sesn2 levels were increased in chronic heart failure patients and were closely related to prognosis.\textsuperscript{15} Until now, the role of Sesn2 in CAVD has not been reported. In this study, we examined Sesn2 expression in CAVD and explored the possible mechanisms.

**MATERIALS AND METHODS**

**Collection of Aortic Valve Tissue**

Diseased and normal aortic valves were collected from patients with CAVD (n = 20) and patients undergoing heart transplantation in the vascular surgery department (n = 10) of the Shanxi Cardiovascular Hospital from 2016 to 2019, respectively. No donors had aortic valve abnormalities caused by other diseases, including congenital diseases, rheumatic heart disease, or endocarditis. All aortic valves were divided into 2 parts and stored in 4% paraformaldehyde and liquid nitrogen for further examination. This study complied with the Declaration of Helsinki. The families of donors signed informed consent forms, and this study was approved by the Ethics Committee of Shanxi Cardiovascular Hospital (approval no. DC.W.2015-11). The clinical characteristics are shown in Supplemental Digital Content 1 (see File, http://links.lww.com/JCVP/A839).

**Cell Culture, Transfection, and Treatment**

Valvular interstitial cells (VICs) and human U937 monocytes were used in this study. VICs were isolated as previously described.\textsuperscript{16} In brief, fresh normal aortic valves were transferred to ultraclean benches and washed with 4°C PBS. Then, the aortic valves were cut into small pieces and digested repeatedly with 1.5% collagenase until completely digested. Then, after being neutralized with FBS, all cells were collected and centrifuged for 10 minutes at 1000g. Furthermore, the cells were cultured in DMEM with 10% FBS, and streptomycin and penicillin G were also added. Human U937 monocytes were purchased from the Cell Center of Wuhan University and cultured in DMEM containing 10% FBS. U937 monocytes were treated with 50 ng/mL macrophage colony-stimulating factor (M-CSF; PeproTech, Cat No.: 300-25-10ug) for 9 days to promote their differentiation into macrophages. In this study, VICs and U937 macrophages at passages 4–6 were used for subsequent experiments.

Small interfering RNA (siRNA) against Sesn2 (si-Sesn2) was transfected into U937 macrophages to decrease Sesn2 expression using Lipofectamine 2000 (RiboBio, Guangzhou) according to the manufacturer’s instructions, and the sequences were described in a previous study.\textsuperscript{7} Complementary DNA (cDNA) targeting Sesn2 (cDNA-Sesn2; RiboBio, Guangzhou) was used to upregulate Sesn2 expression in U937 macrophages, and the sequences were derived from a previous article.\textsuperscript{17} In this study, si-Sesn2 reduced Sesn2 mRNA expression by 71% in U937 macrophages, whereas cDNA-Sesn2 increased Sesn2 mRNA levels by 1.2-fold. The results are shown in Supplemental Digital Content 2 (see Fig. 2, http://links.lww.com/JCVP/A839).

First, U937 macrophages were divided into 5 groups, cultured in calcification medium with 10% FBS, and then pretreated with PBS, siRNA (negative control for si-Sesn2), si-Sesn2, cDNA (negative control for cDNA-Sesn2), and cDNA-Sesn2. Then, U937 macrophages were treated with 100 μg/mL of oxidized low-density lipoprotein (ox-LDL; AngYuBio, Cat No.: AY-1501). Twenty-four hours later, U937 macrophages were collected, and the expression of M1 macrophages and their related markers, as well as Nrf2 levels, were examined. In addition, some of U937 macrophages that were treated with si-Sesn2 and cDNA-Sesn2 were further administered ox-LDL and 2 μM ML385 (MedChemExpress, Cat No.: HY-100523), a specific Nrf2 pathway inhibitor.\textsuperscript{18} Then, oxidative stress was measured, including ROS levels, total SOD activity, GSH levels, and MDA levels. Finally, U937 macrophages were pretreated with si-Sesn2, cDNA-Sesn2, or ML385 and then cocultured with VICs for 24 hours. After treated with PBS or ox-LDL, the mineralization of VICs was examined.

**Western Blot Analysis**

Aortic valve tissue and human U937 macrophages were lysed using RIPA lysis buffer, and total proteins were obtained and adjusted to the same concentration. Total proteins were added to a 10% SDS polyacrylamide gel to electrophoretically separate proteins by their different molecular weights, and all proteins were then transferred to Immobilon-F PVDF membranes. After being blocked with 3% BSA for 90 minutes at room temperature, the membranes were incubated with primary antibodies for 2 hours at 37°C and with secondary antibodies for 1 hour at room temperature. Then, the expression of target proteins was examined by Odyssey. The target proteins in aortic valve tissue were Sesn2 (GeneTex, Cat No.: GTX116925, 1:1500) and GAPDH (GeneTex, Cat No.: GTX100118, 1:5000), and the target proteins in human U937 monocytes were Nrf2 (GeneTex, Cat No.: GTX103322, 1:1500) and GAPDH.

**Immunofluorescence Staining**

Fresh aortic valve tissue was fixed immediately in 4% paraformaldehyde, cut into 4- to 5-μm-thick sections after paraffin embedding, and then transferred onto slides. To measure Sesn2 levels in aortic valve tissue, slides were immunofluorescently stained with Sesn2 antibodies (Abcam, Cat No.: ab236025, 1:150). In addition, double immunofluorescence staining with Sesn2 and F4/80 antibodies (GeneTex, Cat No.: GTX26640, 1:100) was used to determine whether Sesn2 was derived from macrophages. The same methods were used to examine CD86 expression in U937 monocytes and the osteoblastic differentiation of VICs.

**Flow Cytometry**

U937 macrophages were washed with PBS 3 times and collected. Then, U937 macrophages were incubated with fluorescein isothiocyanate (FITC)-conjugated anti-human F4/
Sesn2 Expression is Increased in CAVD Patients

Sesn2 expression was first examined, and the western blot and immunofluorescence results showed that the Sesn2 levels increased approximately 1.1-fold in the CAVD group compared with the normal group (Figs. 1A, B). The double immunofluorescence staining results showed that Sesn2 was highly expressed in the aortic valve macrophages of patients with CAVD (Fig. 1C). The mRNA expression levels of iNOS, Sesn2, ALP, Runx2, and OPN were increased in patients with CAVD (Fig. 2A). In addition, the mRNA levels of Sesn2, ALP, Runx2, and OPN were positively correlated with iNOS mRNA expression in patients with CAVD (Fig. 2B).

Sesn2 Attenuates ox-LDL–induced M1 Macrophage Polarization In Vitro

Flow cytometry showed that neither siRNA nor cDNA affected M1 polarization in ox-LDL–induced U937 macrophages. si-Sesn2 significantly increased the percentage of ox-LDL–induced U937 macrophages, whereas cDNA-Sesn2 exerted the opposite effect (Fig. 3A). Similar trends for CD86 intensity were observed in M1 macrophages (Fig. 3B). In addition, pretreatment with si-Sesn2 increased the mRNA expression levels of CD38, CD80, CD86, and iNOS, whereas pretreatment with cDNA-Sesn2 reduced the mRNA expression of these genes (Fig. 3C).

Sesn2 Alleviates M1 Macrophage-related Oxidative Stress Induced by ox-LDL In Vitro

The effect of Sesn2 on Nrf2 expression was measured, and the results showed that pretreatment with si-Sesn2 decreased Nrf2 expression, whereas pretreatment with cDNA-Sesn2 increased Nrf2 levels in ox-LDL–induced U937 macrophages (Fig. 4A). In addition, treatment with si-Sesn2 increased ox-LDL–induced ROS and MDA levels and decreased SOD activity and GSH levels, whereas treatment with cDNA-Sesn2 decreased ROS and MDA levels and

![FIGURE 1](http://links.lww.com/JCVP/A839)

**FIGURE 1.** Sesn2 levels in aortic valves from patients with CAVD. A and B, Sesn2 expression in normal donors and patients with CAVD was examined by immunofluorescence staining (×400) and western blotting. C, Double immunofluorescence staining with anti-Sesn2 and anti-F4/80 antibodies (×400). N = 10 for the normal group and 20 for the CAVD group. *P < 0.05 versus the normal group.
increased SOD activity and GSH levels (Figs. 4B, C). When the Nrf2 pathway was inhibited by ML385, further ROS and MDA production and lower SOD activity and GSH levels were observed in both the si-Sesn2 and the cDNA-Sesn2 groups (Fig. 4B, C).

**Sesn2 Inhibits ox-LDL–induced Mineralization in VICs In Vitro**

Coculture with macrophages had no effect on ALP, Runx2, or OPN mRNA expression in VICs with or without si-Sesn2 or cDNA-Sesn2 in the absence of ox-LDL (Fig. 5). The mRNA levels of ALP, Runx2, and OPN were increased by ox-LDL and further elevated when si-Sesn2 was also present but were decreased by cDNA-Sesn2 (Fig. 5). The effects of si-Sesn2 and cDNA-Sesn2 on ALP, Runx2, and OPN were reversed by ML385 (Fig. 5).

**DISCUSSION**

CAVD mostly occurs in elderly individuals older than 65 years, and the incidence rate increases with age. CAVD is the third major cause of chronic heart failure in elderly individuals after hypertension and coronary heart disease.19,20 CAVD is one of the most serious public health problems worldwide, greatly reducing the quality of life of patients and even threatening their lives. At present, there is no effective drug to delay the progression of CAVD, and the only effective treatment is aortic valve replacement, which has very strict indications.19,20

---

**FIGURE 2.** iNOS mRNA levels and expression of osteoblastic differentiation markers (VICs) in CAVD. A, The mRNA expression levels in the 2 groups were examined by RT–qPCR. B, Correlation between iNOS mRNA levels and Sesn2, ALP, Runx2, and OPN mRNA levels. N = 10 for the normal group and 20 for the CAVD group. *p < 0.05 versus the normal group.

**FIGURE 3.** Effect of Sesn2 on ox-LDL–induced M1 macrophage polarization in vitro. A, F4/80+CD86+ cells were examined in the 5 groups by flow cytometry. B, CD86 intensity was measured using immunofluorescence staining. C, The mRNA expression levels of CD38, CD80, CD86, and iNOS were investigated by RT–PCR. N = 6 in each group. *p < 0.05 versus the ox-LDL + siRNA or cDNA group.
Therefore, it is important to clarify the pathogenesis of CAVD and find intervention targets to delay its progression. In this study, we found that oxidative stress may be involved in the progression of CAVD, and Sesn2 may delay its progression by reducing oxidative stress, suggesting that Sesn2 may have some value in delaying CAVD progression.

In previous studies on the pathogenesis of CAVD, researchers mostly focused on the osteogenic response of VICs caused by the inflammatory response. It was reported that the infiltration of inflammatory factors, including IL-6, IL-21, IL-32, and IL-37, was significantly increased in the aortic valves of human patients with CAVD. Data from clinical experiments have shown that the proinflammatory factors IL-6 and IL-21 can promote the osteogenic response in VICs in vitro, which may promote the progression of CAVD, whereas the anti-inflammatory factor IL-37 has the opposite effect. Data from animal studies showed that the anti-inflammatory factor IL-37 alleviated the inflammatory response, prevented high-fat diet–induced aortic valve osteogenesis, and delayed the progression of CAVD in mice. However, little attention has been given to the role of oxidative stress in CAVD. Our study showed for the first time that the expression of Sesn2, an antioxidant protein, was significantly increased in the aortic valves of patients with CAVD and was mainly produced by aortic valve macrophages, which is consistent with previous reports. We also found that the mRNA levels of iNOS, an M1 macrophage marker, were positively correlated with both Sesn2 levels and VIC osteoblastic differentiation markers. This result suggests that Sesn2 may be involved in regulating CAVD by regulating M1 macrophage polarization.

Clinically, CAVD is considered to be a biological process that is distinct from atherosclerosis. However, during the progression of CAVD, aortic valve endothelial injury, lipid infiltration and deposition, and the recruitment, infiltration, and polarization of macrophages and T lymphocytes in aortic valves were observed successively, which eventually led to aortic valve fibrosis and calcification. When these injuries are serious, they can cause hemodynamic changes. CAVD is considered to have the same clinical risk factors as arteriosclerosis, such as dyslipidemia, smoking, and old age. Therefore, ox-LDL can be used to simulate the pathological process of CAVD and has been used in animal experiments.
LDL was used to induce the polarization of macrophages, and the effect of Sesn2 on macrophage polarization was examined. The results showed that Sesn2 could significantly reduce the expression of a variety of M1 macrophage markers and the percentage of F4/80+CD86+ cells. These results suggest that Sesn2 can inhibit the polarization of M1 macrophages.

Modern medicine divides macrophages activated by pathological factors into 2 categories: M1 macrophages, which have pro-inflammatory effects, and M2 macrophages, which have anti-inflammatory effects. An increasing number of studies have confirmed that macrophages can also play a strong role in the regulation of oxidative stress, and these cells are one of the main sources of oxidative stress. Compared with M2 macrophages, M1 macrophages play a leading role in a variety of cardiovascular diseases, including hypertension and cardiac injury. Data from clinical studies confirmed that an imbalance in M1 and M2 macrophages was present in the aortic valves of patients with CAVD, suggesting that M1 macrophage–mediated oxidative stress may be involved in the progression of CAVD. Therefore, the effects of Sesn2 on M1 macrophage–mediated oxidative stress were examined, and the results showed that the upregulation of Sesn2 significantly reduced ox-LDL–induced M1 macrophage polarization-induced oxidative stress, suggesting that Sesn2 participates in the progression of CAVD by reducing M1 macrophage–related oxidative stress.

Nrf2 is an important signaling pathway that regulates oxidative stress. Nrf2 activation can induce the downstream HO-1 signaling pathway, inhibit the expression of Nox2 and Nox4, inhibit the expression of oxidants, and promote the expression of antioxidants. Therefore, Nrf2 is thought to be an antioxidant signaling pathway. In a previous study, Xiao et al reported that the effect of upregulated Sesn2 expression on angiotensin II–induced oxidative stress was significantly reversed by silencing the Nrf2 pathway. In another study, Wang et al found that the overexpression of Sesn2 significantly improved neuronal injury induced by cerebral ischemia–reperfusion, and the protective effect of Sesn2 on neural cells was reversed by silencing Nrf2. This evidence suggests that Sesn2 may regulate downstream signals by activating the Nrf2 pathway. In our study, we found that treatment with si-Sesn2 and cDNA-Sesn2 decreased Nrf2 levels and Nrf2 expression, respectively, suggesting that Sesn2 may regulate ox-LDL–induced oxidative stress via the Nrf2 pathway. Next, the Nrf2 pathway was inhibited by ML385, and oxidative stress levels were increased significantly. These results suggest that Sesn2 regulates ox-LDL–mediated oxidative stress through the Nrf2 pathway.

VICs are the most important component of the aortic valve, and their normal function is very important for maintaining the morphology and function of the aortic valve. Osteoblastic differentiation can occur in response to pathological factors such as inflammation and hypoxia, and a large amount of ALP, Runx2, and OPN can be produced, which is a key step in the occurrence of CAVD. Treatment with ox-LDL reduced the mRNA expression of ALP, Runx2, and OPN, which suggests that enhanced oxidative stress may be an important factor in the occurrence of CAVD. Sesn2 also reduces the mineralization of VICs, and this effect was reversed by ML385. These results demonstrate that Sesn2 can alleviate CAVD progression through the Nrf2 pathway by reducing M1 macrophage–related oxidative stress.

In conclusion, our study showed that Sesn2 inhibited the polarization of M1 macrophages and alleviated oxidative stress and VICs osteoblastic differentiation through the Nrf2 pathway to delay the progression of CAVD. Sesn2 may be a target for CAVD prevention.

REFERENCES
1. Kostyunin AE, Yuzhalin AE, Ovcharenko EA, et al. Development of calcific aortic valve disease: do we know enough for new clinical trials? J Mol Cell Cardiol. 2019;132:189–209.
2. Rajamannan NM, Evans FJ, Akawa E, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation. 2011;124:1783–1791.
3. Pan W, Zhou D, Cheng L, et al. Candidates for transcatheter aortic valve implantation may be fewer in China. Int J Cardiol. 2013;168:e133–e134.
4. Ennezat PV, Chiquet C, Mann H, et al. Hastened aortic valve surgery due to calcific retinal embolus in an asymptomatic patient with bicuspid aortic valvular disease. Eur Heart J. 2016;37:2680.
5. Kim MG, Yang JH, Kim KM, et al. Regulation of Toll-like receptor-mediated Sestrin2 induction by AP-1, Nrf2, and the ubiquitin-proteasome system in macrophages. Toxicol Sci. 2015;144:425–435.
6. Xiao T, Zhang L, Huang Y, et al. Sestrin2 increases in aortas and plasma from aortic dissection patients and alleviates angiotensin II-induced smooth muscle cell apoptosis via the Nrf2 pathway. *Life Sci.* 2019; 218:132–138.

7. Yi L, Li F, Yong Y, et al. Upregulation of sestrin-2 expression protects against endothelial toxicity of angiotensin II. *Cell Biol Toxicol.* 2014;30: 147–156.

8. Lanna A, Gomes DC, Muller-Durovic B, et al. A sestrin-dependent Erk-Jnk-p38 MAPK activation complex inhibits immunity during aging. *Nat Immunol.* 2017;18:354–363.

9. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect autophagy to prevent oxidative stress. *Diabetes.* 2020;69:1292–1305.

10. Jegal KH, Ko HL, Park SM, et al. Eupatilin induces Sestrin2-dependent autophagy to prevent oxidative stress. *Apoptosis.* 2016;21:642–656.

11. Liu Y, Cuevas S, Yang S, et al. Sestrin2 decreases renal oxidative stress, lowers blood pressure, and mediates dopamine D2 receptor-induced inhibition of reactive oxygen species production. *Hypertension.* 2014;64:825–832.

12. Liu Y, Li M, Sun M, et al. Sestrin2 is an endogenous antioxidant that improves contractile function in the heart during exposure to ischemia and reperfusion stress. *Free Radic Biol Med.* 2021;165:385–394.

13. Zeng Y, Chi F, Xing R, et al. Sestrin2 protects the myocardium against radiation-induced damage. *Radiat Environ Biophys.* 2016;55:195–202.

14. Wang H, Li N, Shao X, et al. Increased plasma sestrin2 concentrations in patients with chronic heart failure and predicted the occurrence of major adverse cardiac events: a 36-month follow-up cohort study. *Clin Chim Acta.* 2019;495:338–344.

15. Liu Z, Wang Y, Shi J, et al. IL-21 promotes osteoblastic differentiation of human valvular interstitial cells through the JAK3/STAT3 pathway. *Int J Mol Sci.* 2020;17:3065–3072.

16. Zeng Q, Song R, Fullerton DA, et al. Interleukin-37 suppresses M1 macrophage polarization through inhibition of the notch1 and nuclear factor kappa B pathways. *Front Cell Dev Biol.* 2020;8:56.

17. Song J, Zheng Q, Ma X, et al. Predictive roles of neutrophil-to-lymphocyte ratio and C-reactive protein in patients with calcific aortic valve disease. *Int Heart J.* 2019;60:345–351.

18. Ye J, Que B, Huang Y, et al. Interleukin-12p35 knockout promotes macrophage differentiation, aggravates vascular dysfunction, and elevates blood pressure in angiotensin II-infused mice. *Cardiovasc Res.* 2019;115:1102–1113.

19. Ye J, Wang Y, Xu Y, et al. Interleukin-22 deficiency alleviates doxorubicin-induced oxidative stress and cardiac injury via the p38 MAPK/macrophage/Fizz3 axis in mice. *Redox Biol.* 2020;36:101636.

20. Raddatz MA, Hufstatter T, Bersi MR, et al. Macrophages promote aortic valve cell calcification and alter STAT3 splicing. *Arterioscler Thromb Vasc Biol.* 2020;40:e153–e165.

21. Han X, Ding C, Zhang G, et al. Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway. *Biochem Biophys Res Commun.* 2020;525:895–901.